Mark Exley

Mark Exley gained his BS, MS, and PhD. from London University and post-doc at the Dana Farber Cancer Institute, Harvard Medical School (HMS). Mark worked at Immulogic Inc on novel stimulating as well as tolerising vaccines, before returning to HMS as Faculty in 1996. Mark has worked on then newly-emerging human as well as murine CD1d-reactive ‘NKT’ cell populations for over 20 years. Mark was Professor at the University of Manchester, UK and Visiting Professor at HMS 2013-2015, before returning to the US as VP Cellular Immunology at Agenus Inc., retaining honorary appointments at Manchester and HMS. Mark serves on the several SABs as advisor / consultant. His research continues to focus on regulation of immunity by NKT and other immune cells and how this knowledge can be exploited clinically in cancer, inflammatory diseases and autoimmunity, as well as other diseases, such as obesity. He has been pivotal in driving clinical trials of NKT antibody 6B11 that he co-developed in cell therapy and humanized derivative in vivo, as well as other immuno-therapeutic approaches. Mark currently serves as CSO for Imvax Inc.

Companies

• Senior Advisor & SAB Member MiNK Therapeutics (2020)
• Chief Scientific Officer Imvax, Inc. (2020)
• Honorary Professor The University of Manchester (2016)
• Visiting Scientist, Dept. of Medicine Brigham and Women's Hospital, Harvard Medical School (2012)
• VP AgenTus Therapeutics (2018 — 2020)
• VP, Cellular Immunology Agenus (2015 — 2017)
• Professor University of Manchester (2013 — 2015)
• Consultant Agenus (2015 — 2015)
• Co-Founder NKT Therapeutics Inc. (2008 — 2012)

Education

• PhD. The Institute of Cancer Research, U. of London (1986 — 1989)
• Master of Science - MS King's College London (1984.09 — 1986.05)
• Bachelor of Science - BS Imperial College London (1979.09 — 1982.05)